Introduction
Involvement of the short arm of chromosome 3 in various different cancers has been known for some time (Kok et al., 1997) . Frequent allelic loss and homozygous deletions of 3p are one of the earliest molecular changes in tumours of the lung, kidney, head and neck, breast, cervix and gastrointestinal tract (Hung et al., 1995; Kok et al., 1997; Wistuba et al., 2000) . High-resolution studies of tumours refined the areas of allelic losses in 3p into several distinct regions representing likely locations of tumour-suppressor genes (TSGs). These candidate regions include 3p12-13, 3p14.2, 3p21.3, 3p24-25 and 3p25-26 (Hung et al., 1995; Sekido et al., 1998; Sundaresan et al., 1998; Wistuba et al., 2000) . Investigation of these regions has identified resident TSGs, for example VHL at 3p25 and FHIT at 3p14.2, or likely candidates such as DUTT1/ROBO1 at 3p12. Identification of TSGs in the gene-rich 3p21.3 region has been more difficult. Three small cell lung cancer (SCLC) cell lines with overlapping homozygous deletions implicate the 3p21.3 region (Roche et al., 1996; Kok et al., 1997) . Following construction of a B700 kb clone contig covering this deletion overlap and its flanks the transcribed sequences were characterized (Wei et al., 1996; Lerman and Minna, 2000) . Additional discovery of a nesting homozygous deletion in a breast cancer cell line (Sekido et al., 1998) divided the minimal candidate region into a 120 kb region containing 8 genes (HYAL2, FUS1, Ras-associated factor 1 (RASSF1), BLU/ZMYND10, nitrogen permease regulator protein 2-like (NPR2L), 101F6, PL6 and CACNA2D2) and a B250 kb region containing a further 11 genes ( Figure 1) . Thus one or more lung and breast cancer TSGs likely resides in the minimal 120 kb critical deletion region or the larger 250 kb region. Characterization and investigation of all 19 genes has failed to identify significant inactivating mutation rates in lung cancers (Lerman and Minna, 2000) a finding reiterated for individual genes in a variety of other cancer types. Subsequently, several of these genes have been found to be inactivated by novel mechanisms including promoter hypermethylation and the function of some are beginning to be understood. This review will summarize recent findings regarding the candidacy of the eight genes within the 120 kb critical deletion region in cancer.
HYAL2/LUCA2
HYAL2 (hyaluronidase 2, also known as LUCA2) is expressed at high levels in most tissues (including heart, placenta, lung, liver, skeletal muscle and kidney) but absent or poorly expressed in brain (Lepperdinger et al., 1998; Csoka et al., 1999; Lerman and Minna, 2000) . Loss of expression in adult brain is reported to be due to promoter methylation (Lepperdinger et al., 2001 ). Loss of HYAL2 expression was observed by Lerman and Minna (2000) in 8/18 lung cancer cell lines; however, expression was retained in nasopharyngeal carcinoma (NPC) cell lines and xenografts and HYAL2 was not methylated (Chow et al., 2004a) . Furthermore, HYAL2 was not downregulated in four asian esophageal squamous cell carcinoma cell lines (Yi Lo et al., 2006) . No mutations (except for a single complete gene deletion) were observed from 40 lung tumours tested (Lerman and Minna, 2000) . The HYAL2 gene ( Figure 2a ) encodes a 473 amino-acid protein ( Figure 2b ) with a signal peptide (amino acids 1-20), and a calcium binding epidermal growth factor (EGF)-like domain (amino acids 365-469 by SMART prediction). Green fluorescent protein-tagged HYAL2 was shown to have a lysosomal localization (Lepperdinger et al., 1998) , but subsequent work has suggested that HYAL2 is actually a cell surface glycosylphosphatidylinositol anchored protein (Rai et al., 2001) . Although there is some evidence that it may also be produced in a soluble form. HYAL2 is a member of a family of hyaluronoglucosaminidases that includes HYAL1, HYAL3 (3p21.31), HYAL4 and Spam1 (7q31.32). These enzymes degrade hyaluronan (HA), a polysaccharide of repeating D-glucuronic acid (1-b-3) N-acetyl-D-glucosamine (1-b-4), which is a component of the extracellular matrix (ECM). The levels of HA are controlled by the balance of the activities of HA synthase and HYAL enzymes. HA within the ECM is required for many purposes including maintenance of tissue hydration, morphology, embryonic development, wound healing with additional roles in cell communication via binding to cell surface receptors such as CD44 and RHAMM (Toole, 2004) . High levels of HA surrounding tumour cells is often correlated with an aggressive phenotype and poor outcome (Zhang et al., 1995) . Treatment with hyaluronidase induces tumour regression in SCID mice grafted with breast cancer xenographs (Shuster et al., 2002) . Even in haematological malignancies HYAL2 expression has been shown to be inversely correlated with lymphoma aggressiveness (Bertrand et al., 2005) . While high levels of HA appear to be correlated with increased metastatic potential interactions between the cell and matrix need to be temporarily broken, and HYAL function may be necessary for this; a study of glioma cell lines demonstrated that the majority had both raised HA and HYAL2 (Enegd et al., 2002) , indicating that HA turnover or the generation of small HA fragments may be a critical factor in metastasis. HA usually exists as a high-molecular-weight polymer involved in matrix stability and it appears that this form is inhibitory to angiogenesis and endothelial cell proliferation. However, HYAL cleaves HA into short fragments that can stimulate angiogenesis and cell proliferation (see review of HA functions (Toole, 2004) ). Studies of highly invasive breast cancer lines have shown that they preferentially express HYAL2 (Udabage et al., 2005) , perhaps because it is less active than HYAL1 and therefore does not completely digest Figure 1 Schematic representation of the critical 3p21.3 homozygously deleted region. Previously the 3p21.3 region was implicated in lung cancer by the identification of three independent lung cancer homozygous deletions represented by the 370 kb deletion region (diagonally lined bar; NCI-H1450, NCI-H740 and GLC20). Identification of a breast cancer homozygous deletion (black bar, HCC1500) refined the candidate region to 120 kb. Thus one or more tumour-suppressor gene/s could reside in the minimal 120 kb indicated by the breast cancer homozygous deletion or the additional 250 kb indicated by the lung cancer homozygous deletions. These regions are exceptionally gene-rich. The eight genes within the critical 120 kb deletion region and their order are indicated above. HA. It has been suggested that HA degradation occurs via a two-step process; first digestion of high-molecularweight HA to 20 kDa fragments, followed by a slower complete degradation (Csoka et al., 2001; Stern, 2004) . HYAL2 has low (Lepperdinger et al., 1998; Vigdorovich et al., 2005) , or even undetectable (Rai et al., 2001) hyaluronidase activity reported to be optimal pH 4.0 (Lepperdinger et al., 1998) . It is thought that highmolecular-weight HA is tethered to the cell surface by CD44 and HYAL2, particularly in special microdomains (Bourguignon et al., 2004) through which the fragments can become internalized and digestion completed by HYAL1. Even though the level of hyaluronidase activity exhibited by HYAL2 is controversial it is indicated to be physiologically important, not least by the failure to produce viable Hyal2 À/À mice (Lepperdinger et al., 2001) .
HYAL2 has been shown to be the cellular receptor that mediates entry of the jaagsiekte sheep retrovirus (JSRV) (Rai et al., 2001) . JSRV is a betaretrovirus that can infect the epithelial cells of the lower airway of sheep and goats causing a contagious lung cancer known as ovine pulmonary adenocarcinoma, which shares clinical and histological features with human bronchioloalveolar carcinoma, a non-smoking related form of lung cancer. Unlike most transforming retroviruses, which can either induce tumours acutely by capture of oncogenes, or more slowly if they have the potential to activate a proto-oncogene, the protein responsible for JSRV transformation is the viral envelope (Env) protein.
The oncogenic functions of the JSRV Env have recently been reviewed (Liu and Miller, 2007) . Although human HYAL2 can function as a receptor for JSRV it is not reported to cause lung cancer in humans exposed to the virus. However, antisera against the JSRV capsid protein reacts with a third of human pulmonary adenocarcinoma samples suggesting that a related virus may cause human disease (De las Heras et al., 2000) . The ability of the JSRV Env to transform the bronchial epithelial cell line BEAS-2B depends on the activation of MST1R (a cell surface receptor tyrosine kinase also known as receptor tyrosine kinase (RON) that is located at 3p21.31). HYAL2 can bind to and suppress the activity of MST1R (Danilkovitch-Miagkova et al., 2003) and JSRV Env complexed with HYAL2 induces HYAL2 degradation. Therefore, the binding of JSRV to its receptor (HYAL2) may allow MST1R to activate downstream pathways resulting in transformation. Interestingly, hyperactivated MST1R was also found in some human bronchioalveolar carcinomas (Danilkovitch-Miagkova et al., 2003) .
Systematic intravenous (i.v.) administration of a protamine complexed adenovirus vector inducing expression of HYAL2 reduced the number of metastatic foci on the lung surface by 70% (Ji et al., 2002) . However, the same vector was unable to suppress primary tumour growth upon intratumoural injection or to induce apoptosis in vitro. This suggests that in contrast to 101F6, NPRL2 or FUS1 which affected both in vivo and in vitro assays, HYAL2 only exerts its effects at the level of metastasis. Interestingly the related HYAL1 gene had no effect in any of the assays (Ji et al., 2002) . Further evidence for a role in metastasis was found following ectopic overexpression of Xhyal2 in xenopus embryos. In these experiments, overexpression caused a decrease in HA levels and reduced migratory potential of prevascular endothelial cells resulting in defective vessel formation (Mullegger and Lepperdinger, 2002) . In an astrocyte cell line ectopic expression of Hyal2 was found to have no effect on subcutaneous growth; however, it accelerated intracerebral growth of the same cell line (Novak et al., 1999) . This difference may be due to the increased HA levels present in the brain compared with subcutaneously. The opposing results observed by Ji et al. (2002) and Novak et al. (1999) could reflect the different cell lines used; expression of HYAL2 was lost in the non-small cell lung cancer (NSCLC) cells used by Ji et al. (2002) , whereas HYAL2 is not expressed in brain, the source of astrocytes.
FUS1/TUSC2
FUS1 (Figure 3a) is also known as tumour-suppressor gene candidate 2 (TUSC2) and platelet-derived growth factor (PDGF)-associated protein (PAP). The name FUS1 is derived from the fusion junction of the ends of a homozygous deletion found in the SCLC tumour-cell line NCI-H524. Predicted functional motifs (Figure 3b ) suggest FUS1 is a member of the novel cAMPdependent protein kinase A and A kinase-anchoring protein families (Uno et al., 2004) . These protein families participate in numerous cellular processes including cell-cycle progression, signal transduction and apoptosis. FUS1 was originally identified as a PAP that potentiates and inhibits the mitogenic effect of PDGF-A and PDGF-B, respectively (Fischer and Schubert, 1996) suggesting the protein may indeed play A high-stringency motif scan (scansite.mit.edu) identifies a predicted PKC and PKA kinase site (Ser50) and an ERK binding motif. Myristoylation of FUS1 has also been described (Endoh et al., 2005) . ERK, extracellular signal-regulated kinase; PKA, protein kinase A; PKC, protein kinase C.
Evaluation of the 3p21.3 tumour-suppressor gene cluster LB Hesson et al a role in some signal transduction pathways. The protein does not share homology with any other known protein in databases. Mutation of FUS1 in cancer is infrequent and to date no evidence for promoter hypermethylation has been found (Lerman and Minna, 2000; Kondo et al., 2001) . Interestingly, FUS1 protein is lacking in B70% of primary lung tumour cases despite high levels of FUS1 mRNA (Uno et al., 2004) . FUS1 protein is myristoylated (and possibly acylated) in normal cells. However, in tumour cells this posttranslational modification is lacking and this leads to rapid proteasomal-dependent degradation. Overexpression of FUS1 suppresses lung tumour growth, inhibits development of experimental lung metastases in mouse models, induces apoptosis and alters cell-cycle kinetics (Kondo et al., 2001; Ji et al., 2002; Uno et al., 2004) . On the basis of these findings re-introduction of FUS1 has entered phase I/II clinical trials for lung cancer using a nonviral nanoparticle-based systemic gene therapy. Using this method FUS1 does inhibit lung tumour xenograft growth in mice, reduces metastases and prolongs survival, however, this nanoparticle-based systemic therapy is problematic at present due to inflammatory responses Ito et al., 2004) . Myristoylation was found to be essential for FUS1-mediated tumour suppression in vitro and in vivo (Uno et al., 2004) . Thus a deficiency in posttranslational modification frequently leads to instability of FUS1 protein in lung tumour cells effectively resulting in its inactivation despite absence of mutations and in the presence of high levels of transcript mRNA. The physiological role of FUS1 is still unknown and further investigation of this interesting candidate TSG is required.
RASSF1
Of all the genes in the 3p21.3 critical region RASSF1 has been the most comprehensively studied at the genetic, epigenetic and functional level. The RASSF1 gene generates seven transcripts, designated RASSF1A-G, via alternative splicing and differential promoter usage. Two major isoforms RASSF1A and RASSF1C are transcribed from two separate CpG island promoter regions (Figure 4a ). Both contain C-terminal Ras association (RA) domains that share homology with domains in other proteins known to bind Ras including RalGDS and AF-6 (Figure 4b ). The RA domain shares a similar structure with the highly characterized Rasbinding protein Raf. However, whereas effectors such as Raf contain catalytic or other effector domains RASSF1 proteins more likely function as adaptors to recruit additional proteins to receptor complexes. In addition, both RASSF1A and RASSF1C contain C-terminal SARAH (Sav/RASSF/Hpo) domains thought to form a coiled coil and mediate homotypic and heterotypic interactions with other SARAH domain-containing proteins (Scheel and Hofmann, 2003) . RASSF1A also contains a predicted N-terminal diacylglycerol (DAG)-binding domain/protein kinase C conserved 1 (C1) domain not present in RASSF1C. Despite extensive investigation only rare tumour-associated mutations have been identified in NPC, lung, breast and kidney cancer (Lerman and Minna, 2000; Agathanggelou et al., 2005) . Most of these mutations are located in functional domains of RASSF1A. Recently, using a more sensitive methodology, a high incidence of RASSF1 mutations were found in primary NPC tumours (Pan et al., 2005) . Interestingly, however, expression of RASSF1A, but not RASSF1C, is lost or downregulated in a variety of tumours. The principal cause of this loss of expression is tumour-specific RASSF1A promoter CpG island hypermethylation. In the vast majority of cancers, RASSF1C is expressed and its CpG island remains unmethylated. RASSF1A inactivation by methylation was originally described in lung and breast cancers (Dammann et al., 2000) . Since then it has emerged that RASSF1A is one of the most frequently methylated genes so far described in human cancer. Frequent inactivation is observed in a broad spectrum of tumours including SCLC (B80%), NSCLC (B30%), breast (B60%), bladder (35-62%), glioma (B57%), hepatocellular (up to 100%), medulloblastoma (79%), NPC (67%), neuroblastoma (55%), testicular (up to 83%) and many more common cancers (reviewed in Agathanggelou et al., 2005; Hesson et al., 2007) . Associated loss of expression has also been shown in lung, breast, bladder, gastric, cholangiocarcinoma and oesophageal squamous cell carcinoma primary tumours. While allelic loss of RASSF1 is a frequent 'second hit' biallelic inactivation of RASSF1A by promoter hypermethylation can also occur in some tumours (Lusher et al., 2002) . Many studies have shown RASSF1 methylation in cancer may have several clinical utilities. These include its use as a diagnostic marker, a marker for early cancer detection or for patient prognosis. Methylation of RASSF1A seems an ideal cancer biomarker for three main reasons. First, methylation occurs in a very broad spectrum of tumour types. Second, the frequency of methylation is often moderate to very high thus providing a high frequency of diagnostic coverage. Third, methylation of RASSF1A is rare in normal tissues providing a marker with a high specificity. Often RASSF1A methylation is frequently observed in tissues exposed to carcinogens and in more aggressive tumours but very rarely found in normal control samples. For example, RASSF1A methylation is significantly more frequent in bronchial aspirates from current and former smokers and increases in frequency with duration of smoking. Furthermore, methylation can be detected in a range of body fluids such as serum, urine and bronchial aspirates from lung, breast, kidney and bladder cancer patients but not in normal control samples. Thus detection of RASSF1A methylation in body fluids from at risk populations may serve as a powerful adjunct to existing cancer detection methods. For a more comprehensive discussion of RASSF1A methylation in cancer please see Hesson et al. (2007) .
Homology searches of the human genome have identified several other RASSF members that also contain C-terminal RA and SARAH domains ( Figure 4c ). These are RASSF2 (20pter-p12.1), RASSF3 (12q14.1), RASSF4/AD037 (10p11.21), RASSF5/ NORE1 (1q32.1) and RASSF6 (4q21.21). Interestingly, some of these additional members are also inactivated by promoter hypermethylation. RASSF2A expression is frequently lost or downregulated due to tumour-specific promoter CpG island hypermethylation in up to 70% of colorectal carcinomas (CRCs). This is one of the earliest events in CRCs detectable in adenoma polyps (Akino et al., 2005; Hesson et al., 2005) . In fact, inactivation of RASSF2A is much earlier and more frequent in CRCs than inactivation of RASSF1A, which occurs at around 15-45% (Akino et al., 2005; Hesson et al., 2005) . It has recently been shown that methylation in a subset of genes in CRCs and matching faecal tissue may form a basis for early detection (Muller et al., 2004) . The recent data showing early, frequent and tumour-specific RASSF2A methylation in CRCs suggests it would be an ideal molecular biomarker for early detection of CRCs. The feasibility of using RASSF2A methylation as a biomarker for CRCs, perhaps in combination with other genes, is an area of current research in our laboratory. RASSF2A methylation has also been found in gastric cancer at frequencies ranging from 29 to 79% and in 51% of NPC primary tumours (Endoh et al., 2005; Zhang et al., 2007) . In NPC tumours RASSF2A methylation correlates with increased metastatic potential (Zhang et al., 2007) . While RASSF4/AD037 is expressed in a variety of normal tissues, it is lost or downregulated in a variety of tumour-cell lines and primary tumours. In some cases this loss of expression is caused by promoter hypermethylation (Chow et al., 2004b; Eckfeld et al., 2004) . Expression of NORE1A is lost or downregulated in cancer due to promoter hypermethylation (particularly in NSCLC and kidney cancers), while mutation of the NORE1 gene is a rare event (Chen et al., 2003; Hesson et al., 2003; Morris et al., 2003; Irimia et al., 2004) . RASSF3A is not methylated in human tumours and RASSF6 is not methylated in colorectal cancer (Hesson et al., , 2005 Akino et al., 2005) . In addition, RASSF7 and RASSF8 have recently been identified (UCSC Genome Browser; Falvella et al., 2006) . These additional family members also contain a RA domain of the RalGDS/ AF-6 variety but importantly lack SARAH domains. As a result, the function of RASSF7 and RASSF8 may differ considerably from RASSF1-6. Nevertheless, one isoform of RASSF8 is downregulated in lung adenocarcinomas and its re-expression reduces anchorageindependent growth of lung tumour cells (Falvella et al., 2006) . This has been observed for many RASSF members including RASSF1A. Re-expression of RASS-F1A in tumour-cell lines lacking endogeneous expression due to promoter hypermethylation inhibits lung, breast, kidney, prostate, NPC and glioma tumour growth in vitro and tumour formation in vivo in nude mice . It has also been demonstrated using a tetracycline-regulated system that some RASSF1A mutants have significantly reduced tumour-suppressor activity. Furthermore, the S131F mutant, which abolishes a predicted ataxia telangiectasia mutant kinase phosphorylation site, also has less efficient inhibition of tumour growth (Shivakumar et al., 2002) suggesting phosphorylation may be an important factor in the function of RASSF1A. It is also important to note that in some cell backgrounds (prostate and renal cancer cell lines LNCaP and KRC/Y, respectively) RASSF1C re-expression potently suppressed tumour growth in vitro and in vivo in SCID mice suggesting it too could act as a TSG (Li et al., 2004b) . Re-expression of RASSF2A, AD037A and NORE1A also results in suppression of tumour growth in a variety of different tumour types Chen et al., 2003; Vos et al., 2003a, b; Aoyama et al., 2004; Eckfeld et al., 2004; Akino et al., 2005; Zhang et al., 2007) . For several RASSF members growth suppression is enhanced by co-transfection of constitutively active Ras proteins (Vos et al., 2000 (Vos et al., , 2003a or by artificially forcing membrane localization thereby facilitating interaction with Ras (Eckfeld et al., 2004) . Co-immunoprecipitation experiments show that RASSF proteins bind several Ras superfamily members as Ras-guanosine triphosphate (GTP) but not Ras-GDP and that this interaction occurs between the RA domain and the effector domain of Ras proteins (Vavvas et al., 1998; Vos et al., 2000 Vos et al., , 2003a Khokhlatchev et al., 2002; Ortiz-Vega et al., 2002; Eckfeld et al., 2004) . In the case of RASSF1A association with Ras may occur indirectly through heterodimerization with NORE1A or the scaffold protein CNK1 (Ortiz-Vega et al., 2002; Rabizadeh et al., 2004) . Taken together these data indicate the RASSF family of proteins are genuine Ras effectors that mediate some of the growth inhibitory functions of Ras proteins.
To date there have been two reports describing Rassf1a knockout mice. In both studies Rassf1a was specifically targeted by deletion of exon 1a and the resulting Rassf1a knockout mice were healthy and fertile. However, Rassf1a knockout mice have an increased susceptibility to a variety of cancers, including lung and gastrointestinal adenocarcinomas, particularly when exposed to carcinogens such as urethane, ionizing radiation and benzo(a)pyrene van der Weyden et al., 2005) . Although Rassf1a knockout mouse embryonic fibroblast (MEF)s display a slight increase in prometaphase cells relative to wild-type MEFs there is no overt misregulation of mitotic progression or cell-cycle distribution (van der Weyden et al., 2005). However, it is possible that the phenotype of Rassf1a knockout mice and MEFs is partially rescued by functional redundancy with other RASSF members. Drosophila melanogaster, however, has only a single RASSF member known as CG4656 or dRASSF. dRASSF mutant Drosophila, although viable, display a clear growth defect (Polesello et al., 2006) . RASSF1A, and some other RASSF members, can act as tumour suppressors through multiple independent pathways. Overexpression induces dramatic changes in gene expression involving several cell-cycle regulatory genes such as cyclin D (Shivakumar et al., 2002; Agathanggelou et al., 2003a) . Loss of function of RASSF1A leads to a plethora of phenotypic changes due, at least in part, to gross microtubule deregulation. RASSF1A colocalizes with the microtubules, spindles and centrosomes during metaphase and promotes microtubule stability and polymerization Vos et al., 2004) . This colocalization is essential for its growth inhibitory properties. Rassf1a knockout MEFs show an increased sensitivity to the microtubule depolymerizing drug nocodazole (van der Weyden et al., 2005) reiterating that RASSF1A appears to have a role in microtubule stability and polymerization. RASSF1A is associated with microtubules via at least three different proteins. These are the closely related proteins MAP1B and VCY2IP1/C19ORF5 and Cdc20 Song et al., 2004) . Cdc20-APC (anaphase promoting complex) is a central component of the spindle assembly checkpoint during mitosis. APC is a ubiquitin ligase that targets specific proteins for degradation and initiates anaphase in mitotic cells. However, APC activation requires Cdc20 binding. RASSF1A binds Cdc20 via an N-terminal region. This interaction negatively regulates APC, thereby preventing progression beyond the spindle checkpoint in a similar manner to Mad2 (Song et al., 2004) . Using RNAi to deplete RASSF1A and time-lapse microscopy Song et al. (2004) showed that RASSF1A-deficient cells progress from metaphase to telophase more rapidly than RASSF1A-expressing cells. Thus loss of expression of RASSF1A causes premature APC activation, accelerated cell division, various mitotic spindle abnormalities, chromosome mis-alignment and lagging chromosomes during anaphase leading to genomic instability and aneuploidy (Song et al., 2004) . These effects on microtubule dynamics also appear to implicate RASSF1A in the control of cell migration. Overexpression of RASSF1A in lung tumour cells diminished their ability to migrate during woundhealing and caused marked differences in microtubule outgrowth and actin stress fibre formation. Furthermore, siRNA-mediated RASSF1A depletion resulted in highly motile cells with loss of cell-cell adhesion (Dallol et al., 2005) . RASSF1A can inhibit G 1 -S phase transition independently of microtubule regulation by interacting with p120 E4F , a protein known to associate with pRb, p53 and p14 ARF . p120 E4F acts as a transcriptional regulator of proteins important to cell-cycle progression such as cyclin A. Expression of cyclin A is repressed by the binding of p120 E4F to the cyclin A promoter. This binding, and repression of cyclin A expression, is enhanced in the presence of RASSF1A but reduced following siRNA-mediated knockdown of RASSF1A (Ahmed-Choudhury et al., 2005) . Since p120 E4F interacts with the N-terminal region of RASSF1A not found in RASSF1C, these studies identify a transcriptional mechanism through which RASSF1A, but not RASSF1C, can influence cell-cycle progression. However, as mentioned previously RASSF1C may also play a role in some tumours. Recently, Kitagawa et al. (2006) showed RASSF1C colocalizes to the nucleus in complex with Daxx, a protein involved in apoptosis and transcriptional repression. In response to DNA damaging agents such as methylmethane sulphonate or ultraviolet irradiation Daxx undergoes ubiquitination and degradation thereby releasing RASSF1C. This promotes RASSF1C translocation to the cytoplasm where it associates with microtubules and participates in the activation of stress-activated protein kinase/c-jun N-terminal kinase (JNK). Interestingly, while Daxx bound strongly to RASSF1C in co-immunoprecipitation experiments only weak association was observed with RASSF1A (Kitagawa et al., 2006) . This study provides another interesting example of the divergence in function of RASSF1A and RASSF1C.
Several RASSF proteins can also regulate apoptosis. Most notably RASSF1A interacts with the proapoptotic protein kinases MST1 and 2 (mammalian Ste20-like) and MOAP1 (modulator of apoptosis 1) Baksh et al., 2005; Vos et al., 2006) . The Hippo (Hpo) pathway in Drosophila, which controls developmental apoptosis and restricts cell-cycle progression, is canonical to the mammalian MST proapoptotic pathway. Polesello et al. (2006) found that dRASSF and/or Salvador (Sav) directly interact with Hpo through their SARAH domains and this is required for dRASSF and Sav stability. Furthermore, dRASSF and Sav compete for Hpo binding resulting in an active pool of Hpo-Sav and an inactive pool of Hpo-dRASSF complexes. dRASSF may therefore antagonize Hpo activation. Coexpression of RASSF1A and NORE1A with MST also inhibits the phosphorylation of mammalian MST1/2 proteins, as measured by phospho Threonine 183/180 immunoreactivity. Also, addition of RASSF1A and NORE1A protein to MST1 in vitro inhibits MST1 autophosphorylation Praskova et al., 2004; Oh et al., 2006) . However, overexpression of RASSF1A in intact cells enhances MST1 activation and MST1-mediated apoptosis by Fas death receptor signalling. Fas-induced apoptosis was markedly reduced by siRNA depletion of RASSF1A or MST1 and by transfection of cells with RASSF1A[L301P] incapable of MST binding (Oh et al., 2006) . MST proteins are strongly activated by recruitment to the membrane either artificially by modification of RASSF or MST proteins to target them to the membrane or through RASSF binding to activated Ras either directly or through the scaffold protein CNK1 (Praskova et al., 2004; Rabizadeh et al., 2004) . Of particular interest is a recent investigation of binding affinities of the NORE1A, DAG and RA domains. An intramolecular complex can be formed between the RA and DAG-binding domains of NOR-E1A (Harjes et al., 2006) . This interaction is disrupted by Ras-and Rap1-GTP thereby displacing the DAGbinding domain and revealing a lipid-binding interface with a high specificity for phosphatidylinositol 3-phosphate (PI3P). Since RASSF1A also contains DAG-binding and RA domains and is very similar to NORE1A it is likely these properties also apply to RASSF1A. Thus it appears RASSF proteins retain an inactive cytoplasmic MST reservoir in the absence of specific signals but may serve as sensory modules to detect proapoptotic signals initiated through Ras and death receptor pathways. Following apoptotic stimulation, such as tumour necrosis factor-a (TNF-a) death receptor stimulation, RASSF1A can associate with an additional proapoptotic effector, MOAP1, via a C-terminal 312 EEEEH motif within the SARAH domain. This association appears to be necessary for TNF-adependent apoptosis (Baksh et al., 2005) and does not require the BH3-like motif involved in Bax-MOAP1 interaction, thus RASSF1A, MOAP1 and Bax may form a complex in vivo. RASSF1A and MOAP1 interaction promotes Bax conformational change, which is necessary for the integration of Bax into the mitochondrial membrane and the release of cytochrome c. This change in Bax conformation was reversed by siRNA directed against RASSF1A. A role for RASS-F1A in Bax activation is supported by Bax À/À fibroblasts that are resistant to RASSF1A-induced apoptosis (Baksh et al., 2005) .
There has also been a recent report that ion channels can influence the function of RASSF1A. Several isoforms of RASSF1, including A and C, interact with the ubiquitously expressed calcium channel PMCA4b (plasma membrane calmodulin-dependent calcium ATPase 4b). PMCA4b and RASSF1 proteins colocalize to the microtubule network and their interaction appears to inhibit EGF-dependent ERK activation while the S131A mutant does not (Armesilla et al., 2004) . Thus RASSF1A proteins may regulate signalling pathways initiated through ion channels in a phosphorylationdependent manner.
ZMYND10/BLU ZMYND10 (zinc finger, myeloid, nervy and DEAF-1 (MYND)-type containing 10) was initially identified serendipitously using PCR primers to screen for the presence of b-catenin, which was originally assigned to 3p21.3, in a cosmid contig from the region (Lerman and Minna, 2000) . ZMYND10 is expressed in a variety of tissues with high levels observed in lung and testis giving rise to the alternative name BLU (b-catenin in lung). Alternative splicing of BLU/ZMYND10 gives rise to a transcript expressed specifically in testes (Figure 5a ). Mutation of BLU/ZMYND10 is a rare event in lung cancer since missense changes were detected in only 3/61 lung tumour-cell lines (Lerman and Minna, 2000) . Interestingly, however, expression of BLU/ZMYND10 is lost or downregulated in a subset of NPC, lung, neuroblastoma, kidney, breast, esophageal squamous cell carcinoma and glioma tumour-cell lines (Lerman and Minna, 2000; Agathanggelou et al., 2003b; Hesson et al., 2004; Qiu et al., 2004; Yau et al., 2006; Yi Lo et al., 2006) . Promoter CpG island hypermethylation is coincident with loss of BLU/ZMYND10 expression, which can be restored following treatment with the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5azaDC) (Agathanggelou et al., 2003b; Hesson et al., 2004; Qiu et al., 2004; Yau et al., 2006; Yi Lo et al., 2006) . BLU/ZMYND10 hypermethylation and downregulation has been described as a frequent event in primary tumours such as glioma (80%), cervical squamous cell carcinomas (77%), NPC (66%), neuroblastoma (41-70%) and NSCLC (19-43%) with lower frequencies observed in gall bladder carcinomas (26%), ependymomas (13.6%) and SCLC (14%) (Agathanggelou et al., 2003b; Hesson et al., 2004; Qiu et al., 2004; Abe et al., 2005; Ito et al., 2005; Marsit et al., 2005; Lai et al., 2006; Michalowski et al., 2006; Riquelme et al., 2007) . In some tumour types, BLU/ZMYND10 methylation is an early event detectable in stage II glioma and stage I/II cervical squamous cell carcinomas (at frequencies of 88 and 85/68%, respectively) Lai et al., 2006) . In glioma tumours methylation of BLU/ZMYND10 and/or RASSF1A, located adjacent to BLU/ZMYND10, was detected in more than 95% (52/54) primary tumours. Furthermore, in 23% of glioma cases only the methylated BLU/ZMYND10 allele could be detected in the absence of 3p21.3 deletions. Quantitative real-time reverse transcription (RT)-PCR showed the lowest levels of BLU/ZMYND10 expression were observed in tumours exhibiting only the methylated BLU/ZMYND10 allele . Taken together these data suggest that biallelic epigenetic inactivation of BLU/ZMYND10 may occur in gliomagenesis. BLU/ZMYND10 methylation or homozygous deletion was recently found in 83% of NPC (Qiu et al., 2004) . This study also showed that the sequence immediately upstream of exon 1 of the BLU/ZMYND10 gene exhibits promoter activity that can be regulated by environmental stresses, heat shock factor and the transcription factors E2F1, 3 and 4. Transcription of BLU/ZMYND10 may therefore be cell-cycle regulated.
In some cell backgrounds such as neuroblastoma, NSCLC and NPC tumour cells overexpression of BLU/ ZMYND10 is sufficient to reduce colony and tumour formation ability (Agathanggelou et al., 2003b; Yau et al., 2006) . In NPC tumour cells, in which BLU/ ZMYND10 expression is absent, the growth suppressive effects of BLU/ZMYND10 re-expression have been illustrated using a tetracycline-regulated expression system. In the presence of doxycycline, which suppresses expression of re-introduced BLU/ZMYND10, tumour growth following injection into nude mice was similar to recipient or vector-alone transfected cells. However, BLU/ZMYND10 expression in the absence of doxycycline significantly suppressed tumourigenic potential increasing the latency period (time for tumour volume to reach 200 mm 3 ) to 5 to >6 weeks compared with the control of 1-4 weeks (Yau et al., 2006) . Currently, the function of BLU/ZMYND10 is unknown. The most notable feature of the protein is a C-terminal MYND domain (Figure 5b ). The MYND domain is composed of several cysteine and histidine residues with an invariant spacing to form a potential zinc-binding motif. Sequence comparisons of BLU/ ZMYND10 with the human proteome identify several other MYND-containing proteins (such as BS69/ ZMYND11, ETO/MTG family members, DEAF-1 and suppressin) with homology, mainly of residues in and around the MYND domain (Figure 5c ). ETO (eight twenty-one)/MTG (myeloid translocation gene) proteins derive the name from translocations that fuse ETO/ MTG proteins with the acute myelogenous leukaemia 1 (AML1) protein. These translocations create AML1-MTG chimaeric proteins involved in leukaemogenesis due to repression of AML1-regulated transcription during haematopoiesis. Studies of BS69/ZMYND11, MTG8, MTG16, DEAF-1 and suppressin show the MYND domain is essential to many of their functions. The MYND domain constitutes a protein-protein interaction surface that appears to allow these proteins to act as transcriptional co-repressors by association with a variety of chromatin remodelling and transcription factors. MTG8 and MTG16 repress transcription via recruitment of histone deacetylases (HDACs), Sin3a, N-CoR and SMRT (Amann et al., 2001) . BS69/ ZMYND11 binds BRG/SMARCA4 (part of the SNF/ SWI chromatin remodelling complex), HDAC1 (Histone deacetylase 1) and the Histone methyltransferase EZH2 (Velasco et al., 2006) . In addition, the BS69/ and 48% amino-acid identity with human ZMYND17 (NP_001016764), ANKMY2 (NP_064715), MTG8 (NP_783552), EGLN1 (NP_071334), MTG16 (NP_005178), DEAF1 (NP_066288), ZMYND11 (NP_006615) and TDRD1 (NP_942090) and with the D. melanogaster protein nervy (NP_523841). The proteins with the most similar MYND domains to BLU/ZMYND10 are ANKMY2, MTG8 and ZMYND17 with 48, 45 and 45% sequence identity respectively. Across the entire protein length of BLU/ ZMYND10 the most similar were MTG16 and MTG8 with 12 and 13% sequence identity respectively. * Indicates the position of the C523S point mutation that abrogates BS69/ZMYND11 interaction with the histone methyltransferase EZH2 (see Discussion).
Evaluation of the 3p21.3 tumour-suppressor gene cluster LB Hesson et al ZMYND11 mutation C523S abrogates EZH2 binding. C523 is a highly conserved residue found within the MYND domain (Figure 5c ). BS69/ZMYND11 also acts as a transcriptional co-repressor of adenoviral E1A and a variety of transcription factors including ETS2 and CMyb (Hateboer et al., 1995; Ladendorff et al., 2001; Wei et al., 2003) . Repression of adenoviral E1A transactivation occurs through MYND-dependent interaction and recruitment of N-CoR (Amann et al., 2001) . Some other MYND-containing proteins are also candidate TSGs. For example, MTG16 is located at 16q24.3, a region that commonly undergoes allelic loss in breast, prostate and ovarian sporadic cancers. In a similar way to BLU/ ZMYND10, mutation of MTG16 is uncommon in cancer yet expression is downregulated due to promoter CpG island hypermethylation in breast tumour-cell lines and primary tumours (Bais et al., 2004) . Moreover, reexpression of MTG16 reduces colony formation and anchorage-independent growth in soft agar (Kochetkova et al., 2002) . Finally, the MYND-containing protein suppressin has been shown to inhibit cell-cycle entry (LeBoeuf et al., 1998) . In addition to its role as a transcriptional corepressor, BS69/ZMYND11 is also essential in latent membrane protein 1 (LMP1)-mediated activation of the JNK pathway (Wan et al., 2006) . LMP1 is one of nine latent viral antigens expressed in Epstein-Barr virus (EBV)-infected cells. EBV is a transforming DNA virus associated with several malignancies including NPC. BS69/ZMYND11 functions as an adaptor protein bridging LMP1 and TRAF6, a central upstream component in the activation of JNK and other pathways in response to interleukin 1 and bacterial lipopolysaccharide. Activation of TRAF6 by BS69/ZMYND11 appears to be independent of other TRAF6 interacting partners such as TRIF, IRAK1 and IRAK4 thus identifying a novel signalling pathway in EBV-infected cells (Wan et al., 2006) . The MYND domain of BS69/ ZMYND11 is essential for direct interaction with LMP1. Although BLU/ZMYND10, which shares 38% amino-acid identity with BS69/ZMYND11 across the MYND domain, does not appear to interact with LMP1 (Wan et al., 2006) it is tempting to speculate that BLU/ ZMYND10 may participate in a similar way in an as yet unidentified signalling pathway. As a MYND-containing protein BLU/ZMYND10 is most likely to be involved in important transcriptional regulation pathways. Further detailed investigation of BLU/ ZMYND10 function is required before the full consequences of its inactivation can be understood.
NPR2L/NPRL2/TUSC4
NPR2L, also known as TUSC4 (tumour-suppressor candidate 4), is expressed as multiple splice variants in many normal tissues including heart, brain, skeletal muscle, kidney, pancreas and lung (Lerman and Minna, 2000) . Although abundantly expressed in NSCLC tumour-cell lines expression in SCLC tumour-cell lines appears much lower. A 5 0 -CpG island encompasses the transcription start sites of all NPR2L transcript variants ( Figure 6a ). Limited epigenetic investigation has thus far indicated that NPR2L promoter CpG island hypermethylation does not occur in renal tumour-cell lines (Li et al., 2004a) . The major transcript is a 1.5 kb mRNA producing a 380 amino-acid protein encoding a predicted bipartite nuclear localization signal, granulin protein binding domain and a nitrogen permease regulator 2 domain (Figure 6b ). Genetic changes to NPR2L in cancer are more common than previously thought. Initially, a mutation screen of lung tumour-cell lines identified mutations in only 3/38 cases (Lerman and Minna, 2000) . More recently, analysis of ESTs derived from multiple tumour types has identified nonsense deletions and missense mutations. In addition, a series of homozygous deletions of the 3 0 -region of the NPR2L gene was also found in a subset of renal and lung tumour-cell lines (Li et al., 2004a) . These deletions may lead to improper splicing of NPR2L, a hypothesis supported by the identification of unusually large transcripts in all renal tumour-cell lines tested by northern blotting (Li et al., 2004a) . However, these deletions also include other 3p21.3 genes such as RASSF1A and BLU/ZMYND10.
One of the most intriguing studies of NPR2L thus far identified a correlation between the level of expression of NPR2L in tumours and sensitivity to the DNA damaging anticancer drug cisplatin (Ueda et al., 2006) . NPR2L has highly conserved orthologues in several species including yeast. Disruption of yeast Npr2 is involved in cisplatin and doxorubicin resistance in Saccharomyces cerevisiae (Schenk et al., 2003) . In fact, it was this homology with yeast Npr2 that prompted further investigation of human NPR2L with the hypothesis that it shared a similar biological function in determining cellular sensitivity to such chemotherapeutic agents. Indeed, it was found that NPR2L expression was significantly and reciprocally Evaluation of the 3p21.3 tumour-suppressor gene cluster LB Hesson et al correlated with cisplatin sensitivity (P ¼ 0.00001) in NSCLC tumour-cell lines. Moreover, in these cells restoration of NPR2L expression enhanced or resensitized the response to cisplatin in originally cisplatin-sensitive and cisplatin-resistant NSCLC tumour cells, respectively. The efficacy of re-expressing NPR2L in combination with cisplatin treatment was also demonstrated on in vivo tumour growth in an orthotopic mouse model of human NSCLC (Ueda et al., 2006) . In this system, NPR2L expression in NSCLC tumour cells was reactivated in vivo by systemic i.v. injection of nanoparticles containing the NPR2L cDNA driven by the cytomegalovirus promoter. This therefore identifies NPR2L expression as a prognostic indicator of cisplatin response in lung cancer patients in addition to a possible therapeutic strategy of reactivating NPR2L in vivo for enhancing and re-sensitizing non-responders to cisplatin.
Currently, the function of NPR2L is unknown however overexpression in a variety of tumour-cell lines inhibits growth and induces apoptosis (Ji et al., 2002) . Re-expression of physiological levels of NPR2L using a tetracycline-regulated system also suppresses the growth of NSCLC and SCLC tumour cells both in vitro and in vivo in SCID mice (Li et al., 2004a) . Thus NPR2L represents a promising candidate from the 3p21.3 critical region with properties consistent with a role as a TSG.
101F6/CYB561D2
101F6, also known as cytochrome b-561 domain containing 2 (CYB561D2), shares the same promoter CpG island as NPR2L (Figure 7a ). 101F6 encodes a 222 amino-acid protein consisting largely of a cytochrome b-561 ferric reductase transmembrane domain (Figure 7b ). This domain shares significant homology with the family members CYB561D1, CYBRD1 and CYB561. The six known cytochrome b-561 family members are transmembrane proteins involved in electron transfer from extravesicular electron donor proteins to intravesicular electron acceptor proteins. This process is involved in the biosynthesis and activation of various neurotransmitters including dopamine. Although cytochrome b-561 proteins were initially identified in neuroendocrine vesicle membranes, such as adrenal chromaffin granules, they are expressed in many other tissues (Tsubaki et al., 2005) . CYBRD1 (cytochrome b reductase 1) is a ferric reductase associated with the absorption of dietary iron and is mutated in some patients with primary iron overload, a genetically heterogeneous disease affecting iron homeostasis (Zaahl et al., 2004) . 101F6 is highly expressed in placenta, lung and liver with lower levels observed in heart, kidney and pancreas. 101F6 is also highly expressed in lung tumourcell lines and is not commonly mutated in lung cancer (Lerman and Minna, 2000) . These initial observations suggested 101F6 was an unlikely candidate TSG from this region. However, forced expression of 101F6 in NSCLC tumour-cell lines or tumour xenografts, in which 101F6 is either heterozygously or homozygously deleted, significantly reduced cell viability by induction of apoptosis (Ji et al., 2002) . The development of lung metastases in nu/nu mice was also reduced by more than 80% following systemic delivery of 101F6 encoding adenoviral vectors (Ji et al., 2002) . It is therefore possible that haploinsufficiency of 101F6 following allelic loss at 3p21.3 directly contributes to tumour phenotype in the absence of 101F6 mutation or promoter hypermethylation.
PL6/TMEM115
PL6 is encoded by a two exon gene (Figure 8a ) covering 4.8 kb transcribed to form a 2.2 kb mRNA encoding a 351-amino-acid protein (Figure 8b ). PL6 protein is predicted to be an integral membrane protein based on the presence of a predicted N-terminal signal peptide (amino acids 1-46), six transmembrane domains (predicted by SPLIT 4 and TMHMM 2, hence its alternative name TMEM115, transmembrane protein 115) and a DUF1751 domain (characteristic of eukaryotic integral membrane proteins, amino acids 49-151).
Northern analysis demonstrated expression in placenta, lung, liver and pancreas with higher levels in skeletal muscle and kidney, and lower levels in heart and brain, and expression was rarely lost from lung cancer cell lines (Lerman and Minna, 2000) . PL6 is rarely Evaluation of the 3p21.3 tumour-suppressor gene cluster LB Hesson et al mutated in lung cancer (0/78 lung cancer samples sequenced; Lerman and Minna, 2000) , similarly expression was retained in a panel of NPC cell lines and xenographs, and PL6 was demonstrated to be unmethylated in those cell lines (Chow et al., 2004a) .
CACNA2D2
The CACNA2D2 gene (Figure 9a ) is composed from 38 exons covering 140 kb (however, only the centromeric exons encoding the C-terminal end of the protein are located within the minimal region of deletion). Northern blotting detects a 5.5-5.7 kb transcript that is particularly highly expressed in lung and testis but is also detected in brain, heart and pancreas (Gao et al., 2000; Lerman and Minna, 2000) . Initially, expression was additionally reported in heart, skeletal muscle, kidney, liver and placenta (Klugbauer et al., 1999) but this expression has subsequently been attributed to cross hybridization with the similar a2d1 (Gao et al., 2000) . Interestingly expression appears to differ between human and mouse where RT-PCR was unable to detect expression in lung (Barclay et al., 2001) . Alternative splicing generates two forms that differ only in their 5 0 -UTR however a third splice variant which splices in an additional exon (maintaining the reading frame and adding seven amino acids) between exons 22 and 23 has been reported (Lerman and Minna, 2000) . The resulting 1143-amino-acid peptide has a predicted molecular weight of 129 kDa; however, the observed molecular weight is 150 kDa (Gao et al., 2000) . This difference is expected to be accounted for by a high degree of glycosylation at the multiple putative N-glycosylation sites present within the sequence. The protein has a high degree of homology (56% amino-acid conservation) to a2d1 and hence was designated a2d2; the second member of a family of proteins encoding regulatory subunits of voltage activated calcium channels that now contains four genes. The a2d2 protein (Figure 9b ) has an unusually long signal peptide at the N terminus (Brodbeck et al., 2002) and the length of this signal peptide may delay its passage through the endoplasmic reticulum which may be necessary for its high degree of glycosylation (Li et al., 1994) , it is also predicted to have a VWF_A domain (von Willebrand factor, type A domain, commonly involved in multiprotein complexes thus may facilitate the formation of the pore complex; amino acids 291-469), a cache domain (a signalling domain found in Ca 2 þ channel subunits and in prokaryotic chemotaxis receptors (Anantharaman and Aravind, 2000) located at 485-574), and a VWA_N domain, (found at the N terminus of proteins containing von Willebrand factor type A and Cache domains; 141-265). A voltage gated Ca (2 þ ) channel (VGCC) a 2 domain is predicted at 580-666, this domain is commonly found in conjunction with a cache domain in calcium channel a2d subunits. A putative transmembrane helix is predicted at the C terminus (SPLIT 4), and by homology with the well characterized a2d1 it seems likely that the protein is cleaved into its constituent a2 and d subunits that remain linked via a disulphide bond and that the majority of the protein is cytoplasmic and only the d subunit passes through the membrane (Gurnett et al., 1996) .
Calcium channels play a role in the generation of rhythmic membrane potentials in excitable cells, and they act as a pathway through which Ca 2 þ can enter cells, where it can act as a second messenger. Voltage dependent calcium channels are comprised from an a1 subunit that forms the channel pore and voltage sensor and determines the major physical properties of the channel; different a1 subunits control the flow of the different types of Ca 2 þ current (L,N,P/Q,R and T currents). Auxiliary regulatory subunits from the a2d, b and g families are proposed to modulate channel activities. Functional analysis suggests that a2d2 can act as an auxiliary subunit for all three subfamilies of voltage gated calcium channels; co-injection with a1B and b3 increased N type currents (Ca V 2.2), with a1C increased L type currents (Ca V 1.2), or with a1G increased T type currents (Ca V 3.1) (Gao et al., 2000) . Coexpression with a1A and b4 demonstrated that the increase in current was not due to alterations of the voltage dependent properties, but due to alteration of the complex lifetime within the plasma membrane either by increased trafficking or decreased turnover (Brodbeck et al., 2002) .
That a2d2 may play a role in the control of calcium currents in excitable cells was implicated from its cloning from a region syntenic to the region of mouse chromosome 9 to which the spontaneous mouse mutant 'ducky' mapped. This mouse strain, named for its ataxic duck like gait was demonstrated to harbour a mutant cacna2d2 allele (Barclay et al., 2001) and is a mouse model for absence epilepsy with spike wave seizures and cerebellar ataxia. A cacna2d2 mouse knockout was generated and extensively characterized (Ivanov et al., 2004) ; exons 33-39 were replaced with a neomycin resistance cassette; the homozygous null mice were viable, but had an increased frequency of unexplained death, growth retardation, ataxia, increased levels of apoptosis in the granular layer of the cerebellum followed by loss of the cerebellar Purkinje cells, and an increased susceptibility to P2T induced seizures. The homozygous null mice also had an increased frequency of bradycardia, but also a smaller reduction of heart rate in response to isoflurane anaesthesia, suggesting that the sympathetic regulation of cardiac functions is altered in this mouse model (Ivanov et al., 2004) . Similarities between the cacna2d2 null mouse and the cacna1a null mouse (Fletcher et al., 2001) suggested to Ivanov et al. (2004) that the same channel (that is, the Ca V 2.1 channel that regulates P/Q-type currents) was involved and in support of this the P-type currents are reduced in the Purkinje cells of ducky homozygotes (Barclay et al., 2001) . Interestingly, the drug gabapentin which has analgaesic and antiepileptic uses can bind to a2d1 a2d2, but not a2d3 a2d4. This binding reduces the amplitude of the calcium current observed after a polarizing prepulse (but not after stimulation with simple voltage steps) or repetitive depolarizations that mimic the signals observed in refractory epilepsy or pain. This suggests gabapentin binds to the inactive state of a2d1 and a2d2 and promotes maintenance of the inactive state (Alden and Garcia, 2001 ). This effect is seen in dorsal root ganglion cells and skeletal myotubes, but not in cardiac myocytes.
Mutation analysis failed to detect any mutations from 100 lung cancer samples (Lerman and Minna, 2000) ; however, northern analysis demonstrated that while expression was good in normal human lung there was frequent (50%) loss of expression in lung cancer-cell lines, especially NSCLC. Although this may implicate CACNA2D2 as a potential TSG, mice heterozygous for a deletion of exons 33-39 of cacna2d2 appear healthy and have a normal tumour free life span (Ivanov et al., 2004) . Chow et al. (2004a) undertook a study of NPC cell lines and xenografts and in the majority demonstrated loss of expression and concomitant methylation that could be reversed by treatment with 5azaDC; however, analysis of primary tumours demonstrated that methylation was infrequent. A similar situation was observed in gliomas where 4/6 cell lines, but only 1/24 primary tumours were methylated .
That calcium channels may be important in tumorigenesis is not without precedent as the calcium channel related proteins death-associated protein kinase (DAPK) and CACNA1G have been shown to be inactivated in tumours by promoter methylation (Toyota et al., 1999; Zochbauer-Muller et al., 2001; Morris et al., 2003) . Adenoviral mediated transfection of CACNA2D2 into CACNA2D2 null lung cancer cell lines could inhibit cell growth both in vitro and in vivo (Carboni et al., 2003) . The in vitro inhibition of cell growth paralleled an induction of apoptosis and was particularly pronounced in the A549 and H460 lung tumour-cell lines that contain wild-type P53. However, the lung tumour-cell line H358, which has mutant P53, exhibited growth inhibition but did not undergo apoptosis, and the P53 null lung tumour-cell line H1299 neither underwent apoptosis nor growth inhibition in response to CACNA2D2 expression. This suggests that there may be a functional interaction between CACNA2D2 and P53 (Carboni et al., 2003) . Shortly before the cells underwent apoptosis, an increase in free intracellular calcium, followed by depolarization of the mitochondrial membrane, release of cytochrome c and activation of caspase-3 and poly (ADP-ribose) polymerase (PARP) were observed (Carboni et al., 2003) . Thus at least under some circumstances, reexpression of this calcium channel subunit in lung tumour-cell lines can induce apoptosis providing evidence that CACNA2D2 may be a potential TSG in lung cancer.
Discussion
The functions of HYAL2 are still elusive; it has hyaluronidase activity, although how high that level is remains controversial as does the role of HA metabolism in tumorigenesis. HYAL2 has been reported to have both oncogenic and tumour suppressive activities in in vivo assays. These different actions may be the result of differing importance of HA to different types of tumour. HYAL2 is also the receptor through which oncogenic JSRV infects sheep and there is some evidence that this or a related virus may cause human lung tumours.
Perhaps unexpectedly FUS1 has emerged as an interesting candidate from the 3p21.3 critical region. The lack of frequent mutations (only 3/79 lung tumourcell lines and 0/40 primary lung tumours (Lerman and Minna, 2000; Kondo et al., 2001) ) and usual mRNA expression suggested FUS1 was not a likely TSG candidate. However, FUS1 protein is eliminated in a large proportion of lung tumours by degradation due to a defect in post-translational modification. Overexpression of FUS1 results in tumour suppression in vitro and in vivo by mechanisms likely to involve apoptosis and altered cell-cycle kinetics. The finding that FUS1 is myristoylated and that myristoylation is required for tumour suppression highlights the possibility that post-translational modifications may regulate the dynamics of additional genes from the 3p21.3 region.
Given the wealth of data implicating RASSF1A in cancer it is now widely accepted as a bona fide TSG. RASSF1A is frequently inactivated in a huge variety of cancers by promoter hypermethylation, deletion and rarely by mutation. RASSF1A inhibits tumour formation by apoptosis, the regulation of microtubule dynamics and mitotic arrest via multiple effectors (Figure 10 ). Investigation of additional RASSF members has revealed that several have tumour-suppressor activity and are frequently and preferentially inactivated by promoter hypermethylation in cancer. It is likely that further work will continue to provide insights into the importance of this family of genes in cancer. RASSF1A methylation is showing great promise as a diagnostic and prognostic cancer biomarker. The use of hypermethylation as a cancer biomarker requires a panel of several carefully chosen genes that offer the greatest diagnostic coverage and prognostic information for a given cancer. Given the frequencies of RASSF1A methylation, the broad spectrum of tumour types in which this occurs and its potential prognostic value, RASSF1A should be considered for inclusion in any such panel of candidate genes. Assays for loss of expression of genes commonly epigenetically inactivated using microarray technology may also have clinical value as a cancer biomarker. However, in a recent study, global expression profiling of lung tumour cells before and after treatment with 5azaDC failed to detect loss of RASSF1A expression (Shames et al., 2006) . This is because; currently available microarrays do not discriminate between different RASSF1 isoforms, some of which are constitutively expressed.
Genetic evidence of a role for BLU/ZMYND10 in cancer is rapidly accumulating. Although mutations of BLU/ZMYND10 are rare in cancer the gene is inactivated by deletion and promoter hypermethylation very frequently in several cancers, most notably in B80% or more of glioma, NPC and cervical tumours. Inactivation in some cancers is an early event indicating a possible gatekeeper role in tumour formation. BLU/ ZMYND10 re-expression reduces tumorigenicity in some cell backgrounds suggesting that such loss of expression may have profound effects on tumour formation. These data warrant further investigation of BLU/ZMYND10 particularly regarding the function of BLU/ZMYND10 protein in normal cells.
The function of NPR2L is completely unknown. The recent finding that NPR2L expression is reciprocally Figure 10 A summary of the mechanisms of tumour suppression by RASSF1A. RASSF1A can function as a tumour suppressor by regulating apoptosis, microtubule dynamics or cell-cycle progression via multiple effector proteins. RASSF1A can recruit these pathways in response to Ras or Fas-death receptor pathway activation or through some ion channels. Additional RASSF members can also regulate apoptosis through the activation of MST1/2. VCY2IP1 is also known as C190RF5/MAP1S. CNK, connector enhancer of Ksr.
APOPTOSIS MICROTUBULE DYNAMICS CELL CYCLE ARREST
Evaluation of the 3p21.3 tumour-suppressor gene cluster LB Hesson et al associated with the response of lung cancer to cisplatin indicates that NPR2L may play a role in DNA damage response mechanisms. The observation that NPR2L expression is an accurate prognostic indicator of lung cancer cisplatin sensitivity and that its re-expression may re-sensitize nonresponders to cisplatin (Ueda et al., 2006) may also be of significant clinical value. Inactivation of this gene by 3 0 deletions and missense mutations occurs at a moderate frequency in some cancers. Reexpression of physiological levels of NPR2L also suppresses the growth of lung tumour-cell lines in vitro and in vivo indicating the need for further study of this promising candidate.
Despite that 101F6 is well expressed in many lung tumour-cell lines and is not commonly mutated there is evidence that 101F6 deletion in cancer may contribute to tumour growth. In lung cancer cells, in which 101F6 is heterozygously or homozygously deleted 101F6 overexpression reduced tumour growth, the development of lung metastases and induced apoptosis. This suggests haploinsufficiency of 101F6 may be sufficient to contribute to tumour phenotype. It is unclear at present whether re-expression of 101F6 at more physiological levels will also suppress tumour growth. It is also unclear whether 101F6 deletion is merely a bystander effect indirectly fortuitous to tumour growth. Other than the sequence homology observed between other cytochrome b-561 family members and 101F6 there are no additional clues to the function of this gene and its candidacy as a 3p21.3 TSG remains an open question.
PL6 has not been extensively studied; however, from the limited amount of data, PL6 is not mutated in cancer and expression appears to be rarely lost in tumours thus making it a poor candidate TSG.
That CACNA2D2 is well expressed in human lung, and that expression is frequently lost in lung cancer makes it a good potential candidate TSG. However, it does not behave in a classical manner; mouse mutants do not appear to have an increased tumour frequency, and the gene is rarely inactivated by mutation or methylation in primary tumours. While the function of a2d2 in excitable cells is beginning to be characterized, work on its function as a TSG is more limited, but there are suggestions that it may help to regulate mitochondrial membrane potentials and cytochrome c-dependent apoptosis.
It is clear that frequent inactivation of some genes at 3p21.3 can occur by promoter hypermethylation in several tumour types. What is less clear is whether this is a result of a region-wide epigenetic defect that simultaneously inactivates several genes within the region. Some studies have attempted to address this fundamental question by investigating whether hypermethylation of genes from this region are associated. Despite their proximity, BLU/ZMYND10 and RASSF1A methylation mostly appear to be independent events. Methylation of these two genes was not associated in glioma, cervical squamous cell carcinoma or NPC tumours Qiu et al., 2004; Lai et al., 2006) . However, in NSCLC an association was found (Agathanggelou et al., 2003b ). This data is further supported in a report by Ito et al. (2005) , which shows that in NSCLC coincident methylation of two of the three genes SEMA3B (located within the larger B250 kb deletion region at 3p21.3), BLU/ZMYND10 or RASS-F1A was significantly associated. In a recent study of neuroblastoma tumours, methylation of both RASSF1A and BLU/ZMYND10 appear associated (Abe et al., 2005) . Therefore, at least in NSCLC, regional 3p21.3 hypermethylation may be responsible for inactivation of several genes. However, in other tumour types such as glioma, SCLC and NPC inactivation of some 3p21.3 genes by promoter hypermethylation are likely to be independent events and not the result of a region-wide methylation defect. Even if the methylation of BLU/ ZMYND10 and RASSF1A are not associated this does not eliminate simultaneous epigenetic deregulation of several 3p21.3 genes in cancer. For example, in a recent report several genes across the entire chromosomal band 12q14.2 in colorectal tumours were silenced, or expression drastically reduced, despite promoter CpG island hypermethylation occurring in only a subset of these genes. Frigola et al. (2006) went on to demonstrate by ChIP analysis that Histone H3Lys9 methylation across the region in combination with DNA hypermethylation at specific sites was responsible for locking an entire 1Mb region at 12q14.2 in a transcriptionally nonpermissive state. This phenomenon, termed long-range epigenetic silencing (LRES) is not exclusive to 12q14.2 and may be responsible for silencing many other large regions in which there is widespread H3Lys9 methylation. It is intriguing to speculate that the entire deletion region at 3p21.3 could possibly be inactivated by a similar mechanism where DNA hypermethylation at specific sites, such as the RASSF1A, BLU/ZMYND10 or SEMA3B promoter CpG islands, in combination with widespread H3Lys9 methylation may render the region transcriptionally inactive. If this were the case then expression of several contiguous genes within the region would be lost -a genetic lesion analogous to deletion. A detailed and systematic study of promoter DNA hypermethylation, H3Lys9 methylation and quantitative gene expression of the 3p21.3 deletion region will be required to determine if LRES occurs in tumorigenesis. Such an epigenetic fingerprint would aid greatly in understanding the deregulation of expression of genes from this region in cancer. It is worth noting that deciphering the entire epigenome of normal and cancer cells is currently the focus of many laboratories worldwide (Brena et al., 2006) . This International Human Epigenome Project (IHEP) will represent a rich source of information for better understanding the tumorigenic process and for identifying cancer-specific methylation biomarkers. The IHEP will also help our understanding of how environmental factors and stresses control the complex epigenetic code that regulates the dynamics of gene expression during development, aging and disease.
In conclusion, there is now a wealth of evidence indicating the 120 kb critical deletion region at 3p21.3 represents a TSG cluster with preferential inactivation of particular genes depending on tumour type. On the basis of the current genetic, epigenetic and functional data of these genes (summarized in Table 1 ) it is now possible to make the following conclusions. Of the eight genes RASSF1A, BLU/ZMYND10 and FUS1 are likely TSGs in lung and other cancers due to frequent and specific inactivation of these genes in cancer, their ability to suppress tumour growth and known functions consistent with tumour suppression. In addition, FUS1 is already undergoing early clinical trials in lung cancer patients and RASSF1A (plus RASSF2A another RASSF family member) show great promise as molecular markers for early detection. Whether NPR2L, 101F6 and CACNA2D2 are likely candidate TSGs remains an open question. A moderate frequency of mutations and 3 0 deletions of the NPR2L gene occurs in lung and kidney tumours and re-expression of either effectively suppresses tumour growth or induces apoptosis. However, there is a lack of functional data indicating a role in cancer. Finally, other than the inclusion of PL6 and HYAL2 in widespread deletions at 3p21.3 there is little genetic, epigenetic or functional data to suggest they are TSGs. Since the function of many of these genes is largely unknown further investigation is essential if we are to understand fully the role of this region in cancer development. 
